Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer

V. Zlinska, Z. Feketova, A. Czyrek, J. Chudzian, ML. Zivkovic, VC. Ursachi, P. Dudeja, B. Fafilek, J. Rynes, G. Rico-Llanos, A. Koudelka, T. Roy, M. Biadun, V. Raskova, K. Svozilova, M. Stroblova, M. Krzyscik, K. Hristova, D. Krowarsch, S....

. 2025 ; 36 (1) : 102405. [pub] 20241128

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008251

Impaired fibroblast growth factor receptor (FGFR) signaling is associated with many human conditions, including growth disorders, degenerative diseases, and cancer. Current FGFR therapeutics are based on chemical inhibitors of FGFR tyrosine kinase activity (TKIs). However, FGFR TKIs are limited in their target specificity as they generally inhibit all FGFRs and other receptor tyrosine kinases. In the search for specific inhibitors of human FGFR1, we identified VZ23, a DNA aptamer that binds to FGFR1b and FGFR1c with a KD of 55 nM and 162 nM, respectively, but not to the other FGFR variants (FGFR2b, FGFR2c, FGFR3b, FGFR3c, FGFR4). In cells, VZ23 inhibited the activation of downstream FGFR1 signaling and FGFR1-mediated regulation of cellular senescence, proliferation, and extracellular matrix homeostasis. Consistent with the specificity toward FGFR1 observed in vitro, VZ23 did not inhibit FGFR2-4 signaling in cells. We show that the VZ23 inhibits FGFR1 signaling in the presence of cognate fibroblast growth factor (FGF) ligands and its inhibitory activity is linked to its capacity to form unusual G-quadruplex structure. Our data suggest that targeting FGFR1 with DNA aptamers could be an effective alternative to TKIs for treating impaired FGFR1 signaling in human craniosynostoses.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008251
003      
CZ-PrNML
005      
20250422095707.0
007      
ta
008      
250408s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.omtn.2024.102405 $2 doi
035    __
$a (PubMed)39759879
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zlinska, Vladimira $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czechia $u National Centre for Biomolecular Research, Masaryk University, 625 00 Brno, Czechia
245    10
$a Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer / $c V. Zlinska, Z. Feketova, A. Czyrek, J. Chudzian, ML. Zivkovic, VC. Ursachi, P. Dudeja, B. Fafilek, J. Rynes, G. Rico-Llanos, A. Koudelka, T. Roy, M. Biadun, V. Raskova, K. Svozilova, M. Stroblova, M. Krzyscik, K. Hristova, D. Krowarsch, S. Foldynova-Trantirkova, M. Zakrzewska, L. Trantirek, P. Krejci
520    9_
$a Impaired fibroblast growth factor receptor (FGFR) signaling is associated with many human conditions, including growth disorders, degenerative diseases, and cancer. Current FGFR therapeutics are based on chemical inhibitors of FGFR tyrosine kinase activity (TKIs). However, FGFR TKIs are limited in their target specificity as they generally inhibit all FGFRs and other receptor tyrosine kinases. In the search for specific inhibitors of human FGFR1, we identified VZ23, a DNA aptamer that binds to FGFR1b and FGFR1c with a KD of 55 nM and 162 nM, respectively, but not to the other FGFR variants (FGFR2b, FGFR2c, FGFR3b, FGFR3c, FGFR4). In cells, VZ23 inhibited the activation of downstream FGFR1 signaling and FGFR1-mediated regulation of cellular senescence, proliferation, and extracellular matrix homeostasis. Consistent with the specificity toward FGFR1 observed in vitro, VZ23 did not inhibit FGFR2-4 signaling in cells. We show that the VZ23 inhibits FGFR1 signaling in the presence of cognate fibroblast growth factor (FGF) ligands and its inhibitory activity is linked to its capacity to form unusual G-quadruplex structure. Our data suggest that targeting FGFR1 with DNA aptamers could be an effective alternative to TKIs for treating impaired FGFR1 signaling in human craniosynostoses.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Feketova, Zuzana $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia
700    1_
$a Czyrek, Aleksandra $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia
700    1_
$a Chudzian, Julia $u Department of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland
700    1_
$a Zivkovic, Martina Lenarcic $u Slovenian NMR Centre, National Institute of Chemistry, 1000 Ljubljana, Slovenia
700    1_
$a Ursachi, Vlad-Constantin $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia
700    1_
$a Dudeja, Pooja $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia
700    1_
$a Fafilek, Bohumil $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia $u Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czechia
700    1_
$a Rynes, Jan $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czechia
700    1_
$a Rico-Llanos, Gustavo $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia
700    1_
$a Koudelka, Adolf $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia
700    1_
$a Roy, Tanaya $u Department of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
700    1_
$a Biadun, Martyna $u Department of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland
700    1_
$a Raskova, Vendula $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia
700    1_
$a Svozilova, Katerina $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czechia
700    1_
$a Stroblova, Michaela $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia
700    1_
$a Krzyscik, Mateusz $u Department of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
700    1_
$a Hristova, Kalina $u Department of Materials Science and Engineering, Institute for NanoBioTechnology and Program in Molecular Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA
700    1_
$a Krowarsch, Daniel $u Department of Protein Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland
700    1_
$a Foldynova-Trantirkova, Silvie $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czechia
700    1_
$a Zakrzewska, Malgorzata $u Department of Protein Engineering, University of Wroclaw, 50-383 Wroclaw, Poland
700    1_
$a Trantirek, Lukas $u Central European Institute of Technology, Masaryk University, 625 00 Brno, Czechia
700    1_
$a Krejci, Pavel $u Department of Biology, Faculty of Medicine, Masaryk University, 62500 Brno, Czechia $u International Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czechia $u Institute of Animal Physiology and Genetics of the CAS, 60200 Brno, Czechia
773    0_
$w MED00189560 $t Molecular therapy. Nucleic acids $x 2162-2531 $g Roč. 36, č. 1 (2025), s. 102405
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39759879 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095708 $b ABA008
999    __
$a ok $b bmc $g 2306316 $s 1245326
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 36 $c 1 $d 102405 $e 20241128 $i 2162-2531 $m Molecular therapy. Nucleic acids $n Mol Ther Nucleic Acids $x MED00189560
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Možnosti archivace